Literature DB >> 11039781

Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis.

D D Frisbie1, C W McIlwraith.   

Abstract

Joint disease in horses and in humans is a significant social and economic problem and continued research and improvements in therapeutics are needed. Because horses have naturally occurring osteoarthritis that is similar to that of humans, the horse was chosen as a species to investigate gene transfer as a potential therapeutic modality for the treatment of osteoarthritis. Using an established model of equine osteoarthritis, the therapeutic effects resulting from overexpression the equine interleukin-1 receptor antagonist gene sequence through adenoviral mediated gene transfer was investigated. The results of the current study showed intraarticular expression of interleukin-1 receptor antagonist to have favorable effects such as an approximately 28 day upregulation of interleukin-1 receptor antagonist protein expression, significant improvement in clinical parameters of pain and disease activity, and beneficial effects in histologic parameters measured from synovial membrane and articular cartilage when compared with nontransduced joints. Based on the significant improvements seen in this work gene transfer of interleukin-1 receptor antagonist is a practical treatment modality for the equine patient and also offers future promise for human patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11039781     DOI: 10.1097/00003086-200010001-00037

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  7 in total

1.  Benefits of recombinant adeno-associated virus (rAAV)-mediated insulinlike growth factor I (IGF-I) overexpression for the long-term reconstruction of human osteoarthritic cartilage by modulation of the IGF-I axis.

Authors:  Anja Weimer; Henning Madry; Jagadeesh K Venkatesan; Gertrud Schmitt; Janina Frisch; Anna Wezel; Jochen Jung; Dieter Kohn; Ernest F Terwilliger; Stephen B Trippel; Magali Cucchiarini
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies.

Authors:  Roberto Calcedo; Judith Franco; Qiuyue Qin; Dean W Richardson; Jeffery B Mason; Surina Boyd; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2015-06       Impact factor: 2.396

Review 3.  Current and future regenerative medicine - principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicine.

Authors:  Thomas G Koch; Lise C Berg; Dean H Betts
Journal:  Can Vet J       Date:  2009-02       Impact factor: 1.008

4.  Future of adenoviruses in the gene therapy of arthritis.

Authors:  C H Evans; S C Ghivizzani; T A Oligino; P D Robbins
Journal:  Arthritis Res       Date:  2001-02-19

Review 5.  Gene Therapy for Cartilage Repair.

Authors:  Henning Madry; Patrick Orth; Magali Cucchiarini
Journal:  Cartilage       Date:  2011-07       Impact factor: 4.634

6.  Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis.

Authors:  Laurie R Goodrich; Jennifer N Phillips; C Wayne McIlwraith; Stacey B Foti; Joshua C Grieger; Steven J Gray; R Jude Samulski
Journal:  Mol Ther Nucleic Acids       Date:  2013-02-05       Impact factor: 10.183

Review 7.  Animal models for target diseases in gene therapy--using DNA and siRNA delivery strategies.

Authors:  Ian S Blagbrough; Chiara Zara
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.